Countdown to approval: Mesoblast readies for Ryoncil’s FDA milestone
Mesoblast (ASX:MSB; Nasdaq:MESO) has reported significant milestones in its Q1 FY2025 results, including an anticipated FDA decision on its lead product, Ryoncil.
Read MoreTag: MSB
Mesoblast (ASX:MSB) – Webinar Presentation
Silviu Itescu – Managing Director & CEO – Mesoblast Limited (ASX:MSB) is developing innovative allogeneic cellular medicines to treat complex inflammatory diseases. The company’s portfolio of Phase 3 product candidates includes therapies for acute graft versus host disease, chronic heart failure and chronic low back pain.
Read MoreMesoblast (ASX:MSB) – Webinar Presentation
Silviu Itescu – CEO – Mesoblast (ASX:MSB) is using its proprietary mesenchymal lineage cell technology platform to develop and commercialise innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care.
Read MoreStocks of the Hour: Mesoblast, Andromeda Metals, Imugene
A snapshot of the stocks on the move, featuring Mesoblast (ASX:MSB), Andromeda Metals (ASX:ADN) and Imugene (ASX:IMU).
Read MoreMesoBlast (ASX: MSB) – Webinar Presentation
Silviu Itescu – Chief Executive Officer & Managing Director – Mesoblast uses its proprietary technology platform to develop and commercialise innovative allogeneic cellular medicines to treat complex diseases resistant to conventional standard of care and where inflammation plays a central role.
Read MoreCSL Finally Confirms $A16 Billion Vifor Deal
CSL announced late Tuesday that it has struck a deal to buy Swiss-based Vifor Pharma Ltd for $A16.4 billion, its biggest deal since listing in 1994.
Read MoreMesoblast, COVID-19 And Trump?
As an analyst who follows biopharma companies, I take an interest in the US Food and Drug Administration (FDA), while as an American/Australian, US politics, particularly, in the days of Trump, is also an interest. Then, there is an ASX-listed cellular therapy company called Mesoblast (ASX:MSB), which I have followed pretty much since it listed in 2004.
Read MoreSmall Cap Biotech’s Under The Microscope
After some earlier positive trial results, the biotech sector is seeking treatment after some less than impressive results. But does value remain for investors?
Read MoreBiotech Update: Mesoblast & Acrux
Listed-Australian biotechnology companies can be split into two groups, drug development companies and medical device companies.
Read MoreMesoblast Implodes As Key Partner Walks
Shares in biotechnology company Mesoblast (MSB) were slammed yesterday after a key research partner walked away from research work underway into a treatment for chronic heart failure. Analysts said it was the second bit of negative news for Mesoblast’s main research program
Read MoreMesoblast Blasted Higher
Mesoblast (MSB) was the day’s hot stock yesterday with the shares leaping more than 24% after it became known that US global biotech, Celgene has picked up a 4.7% stake in the Australian company and was looking for closer co-operation.
Read More
